Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Weight Management: early-phase trial registry

6 of 9 indexed Weight Management trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Weight Management: 9 US clinical trials tracked, 6 recruiting.

Weight Management is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Graviton Bioscience Corporation, running 1 of these trials.

Enrollment posture brief

Registry condition weight-management

OPEN 6 | RECR 67% | LATE 0 | EARLY 3 | RANK #1916 | SPON 1

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Weight Management (this)67%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Weight Management

Weight Management lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Weight Management on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Weight Management is recruiting above its size-band peers.

    6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Weight Management trials is spread across many organizations.

    Graviton Bioscience Corporation accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Weight Management enrolment sits around 50 participants.

    Median target enrolment is 50 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Weight Management research is mostly interventional.

    7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Named interventions

Most-linked intervention names on Weight Management records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
GV101 placebo Drug
1 trials
GV101 Drug
1 trials
Identical placebo capsule. Other
1 trials
Ashwagandha 300 mg standardized root extract Dietary supplement
1 trials
CE-326,597 5mg QD Drug
1 trials
CE-326,597 25 mg QD Drug
1 trials
CE-326,597 50 mg QD Drug
1 trials

US sites by state

Facility locations filed on Weight Management trials. A trial with sites in several states counts in each.

California 3 trials
Utah 2 trials
Texas 2 trials
North Carolina 2 trials
Missouri 2 trials
Kentucky 2 trials
Kansas 2 trials
Florida 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Weight Management page

9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Weight Management condition card totals 9 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.